Ambrisentan
Who holds supplier records for Ambrisentan? 9 organisations hold a current record for Ambrisentan: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (5), China (2) and Malta (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Ambrisentan: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/ambrisentan
Reading the evidence
- 9 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
5 of the 8 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Ambrisentan expires 14 Oct 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (9)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Ambrisentan. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Cipla LimitedIndia Company GMP cert on recordActive DMF 29490 · latest filing Jun 2015
- JIANGSU JOYGLORY PHARMACEUTICAL CO LTDActive DMF 30799 · latest filing Jul 2016
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 24505 · latest filing Dec 2010
- MEDICHEM MANUFACTURING (MALTA) LTDMalta Company GMP cert on recordActive DMF 28781 · latest filing Nov 2014
- Megafine PharmaIndiaActive DMF 29792 · latest filing Sept 2015
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 26156 · latest filing Jun 2012
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 36105 · latest filing Jul 2021
- Tianjin Weijie Pharmaceutical Co., Ltd.ChinaActive DMF 31133 · latest filing Dec 2016
- Zhejiang Huahai Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 27505 · latest filing Sept 2013
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Ambrisentan are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- India · Inactive DMF 25134 · filed Sept 2011
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (16 listed products contain Ambrisentan). The latest listed patent expires 14 Oct 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Ambrisentan is an endothelin receptor antagonist used to treat pulmonary arterial hypertension, improving exercise ability and delaying clinical worsening. It works by selectively blocking the endothelin type-A receptors, leading to vasodilation.
Chemical identity
- IUPAC name
- (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
- Canonical SMILES
- CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
- InChIKey
- OUJTZYPIHDYQMC-LJQANCHMSA-N
- Synonyms
- Letairis API, ambrisentan, (+)-, gsk-1325760, gsk-1325760a, gsk1325760, gsk1325760a, letairis, lu-208075, volibris
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Endothelin Receptor Antagonist
- Mechanism of action
- Endothelin Receptor Antagonists
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Ambrisentan?
9 organisations hold an active US FDA Type II Drug Master File or a CEP for Ambrisentan: Cipla Limited (India), JIANGSU JOYGLORY PHARMACEUTICAL CO LTD, MATRIX PHARMACORP PRIVATE LTD (India), MEDICHEM MANUFACTURING (MALTA) LTD (Malta), Megafine Pharma (India), MSN Laboratories Private Limited (India), Sun Pharmaceutical Industries Limited (India) and Tianjin Weijie Pharmaceutical Co., Ltd. (China), and 1 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Ambrisentan Drug Master Files are active?
Cipla Limited (DMF 29490), JIANGSU JOYGLORY PHARMACEUTICAL CO LTD (DMF 30799), MATRIX PHARMACORP PRIVATE LTD (DMF 24505), MEDICHEM MANUFACTURING (MALTA) LTD (DMF 28781), Megafine Pharma (DMF 29792), MSN Laboratories Private Limited (DMF 26156), Sun Pharmaceutical Industries Limited (DMF 36105) and Tianjin Weijie Pharmaceutical Co., Ltd. (DMF 31133) and 1 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Ambrisentan records mean?
1 organisation has only inactive Type II DMFs for Ambrisentan. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Ambrisentan?
Yes. The latest patent listed for an approved US product containing Ambrisentan expires 14 Oct 2031, across 16 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Ambrisentan supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Ambrisentan?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.